Dotan Shaniv

Mr. Dotan Shaniv

Pharmacy Services, Kaplan medical center, Reẖovot, Central, Israel
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

17 July 2017 in Birth Defects Research
Verified
Journal Article
Closed access
PDF file
NKNirit Kronenfeld
Nirit Kronenfeld
MBMaya Berlin
Maya Berlin
DSDotan Shaniv
Dotan Shaniv
MBMatitiahu Berkovitch
Matitiahu Berkovitch

8 May 2023 in Children
Verified
Journal Article
Open access
PDF file
DSDotan Shaniv
Dotan Shaniv
Srinivas BolisettySrinivas Bolisetty
Srinivas Bolisetty
TYThomas E. Young
Thomas E. Young
BMBarry Mangum
Barry Mangum
SASean Ainsworth
Sean Ainsworth
Karel AllegaertKarel Allegaert
Karel Allegaert
Neonatal drug information (DI) is essential for safe and effective pharmacotherapy in (pre)term neonates. Such information is usually absent from drug labels, making formularies a crucial part of the neonatal clinician’s toolbox. Several formularies exist worldwide, but they have never been fully mapped or compared for content, structure and workflow. The objective of this review was to identify neonatal formularies, explore (dis)similarities, and raise awareness of their existence. Neonatal formularies were identified through self-acquaintance, experts and structured search. A questionnaire was sent to all identified formularies to provide details on formulary function. An original extraction tool was employed to collect DI from the formularies on the 10 most commonly used drugs in pre(term) neonates. Eight different neonatal formularies were identified worldwide (Europe, USA, Australia-New Zealand, Middle East). Six responded to the questionnaire and were compared for structure and content. Each formulary has its own workflow, monograph template and style, and update routine. Focus on certain aspects of DI also varies, as well as the type of initiative and funding. Clinicians should be aware of the various formularies available and their differences in characteristics and content to use them properly for the benefit of their patients.

6 May 2017 in Drugs & Aging
Verified
Journal Article
Closed access
PDF file
JTJacques Theitler
Jacques Theitler
ABAnna Brik
Anna Brik
DSDotan Shaniv
Dotan Shaniv
MBMatitiahu Berkovitch
Matitiahu Berkovitch
RGRevital Gandelman-Marton
Revital Gandelman-Marton

1 January 2019 in Therapeutic Advances in Chronic Disease
Verified
Journal Article
Open access
PDF file
MBMaya Berlin
Maya Berlin
DBDana Barchel
Dana Barchel
RGRevital Gandelman-Marton
Revital Gandelman-Marton
NBNurit Brandriss
Nurit Brandriss
IBIlan Blatt
Ilan Blatt
MBMatitiahu Berkovitch
Matitiahu Berkovitch
Epilepsy is one of the most common chronic neurological conditions and its treatment during pregnancy is challenging. Levetiracetam (LEV) is an antiepileptic medication frequently used during pregnancy. Only a few small studies have been published on LEV monitoring during pregnancy, demonstrating decreased serum LEV levels during the first and second trimester; however, the most significant decrease was observed during the third trimester of pregnancy. In this study we aimed to evaluate LEV pharmacokinetics during different stages of pregnancy. We followed up and monitored serum levels of pregnant women treated with LEV for epilepsy. Fifty-nine women with 66 pregnancies during the study period were included. The lowest raw LEV serum concentrations were observed during the first trimester. Compared with the pre-pregnancy period, raw serum concentration was lower by 5.76 mg/L [95% confidence interval (CI) (2.78, 8.75), p = 0.039] during the first trimester. Comparing the decrease in the first trimester with either the second or the third, no significant changes were observed (p = 0.945, p = 0.866). Compared with pre-pregnancy measurements, apparent clearance was increased by 71.08 L/day [95%CI (16.34, 125.83), p = 0.011] during the first trimester. About 30% of LEV serum levels during pregnancy were below the laboratory quoted reference range. Raw LEV serum levels tend to decrease during pregnancy, mainly during the first trimester contrary to previous reports. Monitoring of LEV serum levels is essential upon planning pregnancy and thereafter if pre-pregnancy LEV levels are to be maintained. However, more studies are needed to assess the correlation with clinical outcome.

21 November 2017 in Frontiers in Pharmacology
Verified
Journal Article
Open access
MBMatitiahu Berkovitch
Matitiahu Berkovitch
Liat Ashkenazi-HoffnungLiat Ashkenazi-Hoffnung
Liat Ashkenazi-Hoffnung
IYIlan Youngster
Ilan Youngster
DSDotan Shaniv
Dotan Shaniv
DDDorit Dil-Nahlieli
Dorit Dil-Nahlieli
ESEyal Schwartzberg
Eyal Schwartzberg
Benzathine Penicillin G (BPG) is commonly used for treatment of penicillin-susceptible infections and secondary prevention of rheumatic fever. Death following administration of BPG is extremely rare—only a handful of cases have been described in the literature since the 1950's. In this case series from Israel and Switzerland, we describe nine cases of serious adverse reactions—six fatal reactions and three near-fatalities—occurring within minutes of receiving intramuscular BPG. Allergic reactions or faulty administration were not implicated in any of the cases; however, all patients had cardiac risk factors. This case series describes a relatively rare risk that should be borne in mind when prescribing BPG.